---
schema_version: "secwatch.filing_event.v1"
accession: "0001846253-25-000064"
form_type: "8-K"
ticker: "OABI"
cik: "0001846253"
company_name: "OmniAb, Inc."
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T19:56:14.126111+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# OmniAb reports Q2 2025 revenue $3.9M, net loss $15.9M; affirms $20-25M FY revenue guidance

## Summary
- Q2 revenue $3.9M (down 49% YoY) on lower milestone and service revenue; net loss $15.9M ($0.15/sh) vs $13.6M ($0.13) in Q2 2024.
- 2025 guidance: revenue $20M-$25M, operating costs $85M-$90M, cash use expected below 2024's $38.9M (ex-ATM).
- 100 active partners and 381 active programs as of June 30, 2025, including 32 OmniAb-derived programs in clinical development.
- Sold small-molecule Kv7.2 program to Angelini Pharma for $3M upfront; eligible for >$170M milestones plus royalties.
- Launched xPloration Partner Access Program for high-throughput B-cell screening; xPloration won 2025 Best of Show at PEGS Boston.

## SEC filing metadata
- accession: 0001846253-25-000064
- form_type: 8-K
- ticker: OABI
- cik: 0001846253
- company_name: OmniAb, Inc.
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1846253/000184625325000064/0001846253-25-000064-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1846253/000184625325000064/oabi-20250806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001846253-25-000064
- JSON: https://secwatch.observer/filing/0001846253-25-000064.json
- Plain text: https://secwatch.observer/filing/0001846253-25-000064.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.